Citations

Clear

14 citation(s) found for "Li, Yulan".

Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Patients With Barrett Esophagus
Laun, Sarah , Kann, Lisa , Braun, Jerome J., Pierre, Francia , Kim, Suji , Gilbert, Stacey, Lunz, Daniel, Kalra, Andrew , Cheng, Yulan , Leggett, Cadman L. , Omstead, Ashten N., Korman, Louis Y. , Jobe, Blair A. , Perpetua, Lorrie A., Greenwald, Bruce D. , Maddala, Tara, Meltzer, Stephen J. , Leggett, Cadman L , Zaidi, Ali Hussainy , Greenwald, Bruce D , Meltzer, Stephen J , Braun, Jerome, Ma, Ke

Mayo Clinic

American Journal of Gastroenterology | February 11, 2025 | Volume: 120 | Issue: 6 | Pages: 1285-1295

10.14309/ajg.0000000000003367 | PMID 39933887 Get It

INTRODUCTION: Barrett esophagus (BE) is the strongest known risk factor for developing esophageal adenocarcinoma (EAC), the second-most lethal cancer in the United States. Esopredict is a novel validated methylation-based biomarker assay that provides precise quantification of neoplastic progression risk in BE patients. Inherit challenges, including tissue heterogeneity, sampling error, interobserver variability, and inconsistent adherence to surveillance biopsy guidelines, may affect the predictive value results of Esopredict obtained at different anatomic locations or different sampling time points. METHODS: To investigate the spatiotemporal performance of Esopredict across multiple spatiotemporal sampling points, we profiled 220 biopsies obtained from 58 BE patients, including 11 patients with overlapping spatial and temporal biopsies. We focused on spatial profiling (i.e., multiple biopsies obtained at several anatomic locations during a single endoscopy) and temporal profiling (i.e., biopsies obtained from multiple endoscopies performed at different time points). Each patient had an initial histologic diagnosis of nondysplastic Barrett esophagus, indefinite for dysplasia, or low-grade dysplasia. Final follow-up (endpoint) biopsies showed either high-grade dysplasia or EAC (progressors), or nondysplastic Barrett esophagus, indefinite for dysplasia, or low-grade dysplasia (nonprogressors). Biopsies were analyzed with Esopredict to compute a progression risk score, which quantified the likelihood of future progression to high-grade dysplasia or EAC within 5 years. RESULTS: In 52 spatially profiled patients, Esopredict demonstrated a sensitivity of 81% (17/21 progressor patients), based on the highest-scoring biopsy from each patient; sensitivity increased to 100% (12/12) when end point biopsies occurred within 5 years of the index (initial) biopsy. In 28 temporally profiled patients, sensitivity was 100% (8/8 patients), based on the biopsy performed at the time point closest to the end point biopsy. DISCUSSION: Esopredict showed high predictive performance in multiple spatiotemporal samples in BE patients. These data further support the use of Esopredict as a robust test to distinguish high-risk BE patients, who may benefit from endoscopic eradication therapy or increased surveillance frequency, from low-risk patients, who may be candidates for less frequent surveillance and noninterventional observation.
A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy
Lukes, Andrea S. , Ferreira, Juan-Camilo Arjona, Li, Yulan , Hunsche, Elke , Wagman, Rachel B., Stewart, Elizabeth A. , Venturella, Roberta , Al‐Hendy, Ayman

Mayo Clinic

Pain Management | October 28, 2024 | Volume: 14 | Issue: 9 | Pages: 469-476

10.1080/17581869.2024.2408114 | PMID 39466126 Get It

Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett Esophagus
Laun, Sarah , Kann, Lisa , Braun, Jerome J., Gilbert, Stacey, Lunz, Daniel, Pierre, Francia , Kalra, Andrew , Tsai, Hua‐Ling , Wang, Hao , Cheng, Yulan , Ahmed, Yousra , Wang, Kenneth K, Leggett, Cadman L. , Cellini, Ashley, Ioffe, Olga B. , Omstead, Ashten N., Jobe, Blair A. , Korman, Louis Y. , Cornish, Drew, Zellenrath, Pauline A. , Perpetua, Lorrie A., Greenwald, Bruce D. , Maddala, Tara, Meltzer, Stephen J. , Tsai, Hua-Ling , Wang, Hao , Ahmed, Yousra , Leggett, Cadman L , Ioffe, Olga B , Zaidi, Ali Hussainy , Cornish, Drew , Zellenrath, Pauline , Spaander, Manon , Kuipers, Ernst , Greenwald, Bruce D , Meltzer, Stephen J , Braun, Jerome, Ma, Ke , Jit, Simran, Kuipers, Ernst J.

Mayo Clinic

American Journal of Gastroenterology | August 14, 2024 | Volume: 120 | Issue: 6 | Pages: 1296-1306

10.14309/ajg.0000000000003030 | PMID 39140473 Get It

INTRODUCTION: Esophageal adenocarcinoma (EAC) is the second-most lethal cancer in the United States, with Barrett esophagus (BE) being the strongest risk factor. Assessing the future risk of neoplastic progression in patients with BE is difficult; however, high-grade dysplasia (HGD) and early EAC are treatable by endoscopic eradication therapy (EET), with survival rates of 90%. Thus, it would be beneficial to develop a molecular assay to identify high-risk patients, who merit more frequent endoscopic surveillance or EET, as well as low-risk patients, who can avoid EET and undergo less frequent surveillance. METHODS: Deidentified endoscopic biopsies were acquired from 240 patients with BE at 6 centers and confirmed as future progressors or nonprogressors. Tissues were analyzed by a set of methylation-specific biomarker assays. Test performance was assessed in an independent validation set using 4 stratification levels: low risks, low-moderate risks, high-moderate risks, and high risks. RESULTS: Relative to patients in the low-risk group, high-risk patients were 15.2 times more likely to progress within 5 years to HGD or EAC. For patients in the high-risk category, the average risk of progressing to HGD or EAC within 5 years was 21.5%, 4-fold the BE population prevalence within 5 years, whereas low-risk patients had a progression risk of only 1.85%. DISCUSSION: This clinical assay, Esopredict, stratifies future neoplastic progression risk to identify higher-risk patients with BE who can benefit from EET or more frequent surveillance and lower-risk patients who can benefit from reduced surveillance.
Treatment of uterine fibroid symptoms with relugolix combination therapy
Al‐Hendy, Ayman , Lukes, Andrea S. , Poindexter, Alfred N., Venturella, Roberta , Villarroel, Claudio , Li, Yulan , McKain, Laura , Ferreira, Juan Camilo Arjona , Langenberg, Andria, Wagman, Rachel B., Venturella, Roberta , Critchley, Hilary , Stewart, Elizabeth A.

Mayo Clinic

Reproductive health of woman | July 30, 2024 | Volume: No volume available | Issue: 4 | Pages: 53-62

10.30841/2708-8731.4.2024.308996 Get It

Uterine fibroids are a common cause of heavy menstrual bleeding and pain. Treatment with the combination of relugolix (an oral gonadotropin-releasing hormonereceptor antagonist), estradiol, and norethindrone acetate, administered once daily, may have efficacy in women with uterine fibroids and heavy bleeding while avoiding hypoestrogenic effects. Methods. We conducted two replicate international, double-blind, 24-week, phase 3 trials involving women with fibroid-associated heavy menstrual bleeding. Participants were randomly assigned in a 1:1:1 ratio to receive once-daily placebo, relugolix combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate), or delayed relugolix combination therapy (40 mg of relugolix monotherapy, followed by relugolix combination therapy, each for 12 weeks). The primary efficacy end point in each trial was the percentage of participants with a response (volume of menstrual blood loss <80 ml and a ≥50% reduction in volume from baseline) in the relugolix combination therapy group, as compared with the placebo group. Key secondary end points were amenorrhea, volume of menstrual blood loss, distress from bleeding and pelvic discomfort, anemia, pain, fibroid volume, and uterine volume. Safety and bone mineral density were assessed.Result. A total of 388 women in trial L1 and 382 in trial L2 underwent randomization. A total of 73% of the participants in the relugolix combination therapy group in trial L1 and 71% of those in trial L2 had a response (primary end point), as compared with 19% and 15%, respectively, of those in the placebo groups (P<0.001 for both comparisons). Both relugolix combination therapy groups had significant improvements, as compared with the placebo groups, in six of seven key secondary end points, including measures of menstrual blood loss (including amenorrhea), pain, distress from bleeding and pelvic discomfort, anemia, and uterine volume, but not fibroid volume. The incidence of adverse events was similar with relugolix combination therapy and placebo. Bone mineral density was similar with relugolix combination therapy and placebo but decreased with relugolix monotherapy.Conclusions. Once-daily relugolix combination therapy resulted in a significant reduction in menstrual bleeding, as compared with placebo, and preserved bone mineral density in women with uterine fibroids.
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary
Lukes, Andrea S. , Li, Yulan , Hunsche, Elke , Wagman, Rachel B., Stewart, Elizabeth A. , Venturella, Roberta , Al‐Hendy, Ayman

Mayo Clinic

Journal of Comparative Effectiveness Research | June 27, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.57264/cer-2023-0194 | PMID 38934918 Get It

What is this summary about? This is a summary of findings from two research studies (known as clinical trials). The studies looked at how well a medicine called relugolix combination therapy worked in women with heavy menstrual bleeding (heavy bleeding during a period) with uterine fibroids (noncancerous or benign growths in the uterus). In this analysis of the studies, researchers looked at how patients self-reported their uterine fibroid symptoms before and after taking relugolix combination therapy. Researchers also looked at how patients self-reported the impact of uterine fibroids on their health-related quality of life before and after taking relugolix combination therapy. What were the results? Women took either relugolix combination therapy or placebo (a pill that contains no medicine) by mouth once daily for 24 weeks. Women completed the Uterine Fibroid Symptom and Quality of Life questionnaire (where “quality of life” refers to the women's health-related quality of life related to uterine fibroids) before, during, and after treatment. The questionnaire let researchers see if the women felt that relugolix combination therapy decreased the burden of uterine fibroid symptoms and improved the women's health-related quality of life related to uterine fibroids. More women said that they felt less distress due to their uterine fibroid symptoms and that their health-related quality of life related to uterine fibroids was better after taking relugolix combination therapy compared with women who took placebo. What do the results mean? Relugolix combination therapy may lessen distress associated with uterine fibroid symptoms and improve health-related quality of life related to uterine fibroids.
Single-cell and spatial transcriptomics uncovers the role of senescent vascular cells in pathological arterial remodeling during atherosclerosis
Mazan-Mamczarz, Krystyna , Tsitsipatis, Dimitrios , Carr, Angelica E. , Santos, Carla Rocha Dos, Anerillas, Carlos , Romero, Brigette , Gregg, Jordan , Michel, Marc, Munk, Rachel , Piao, Yulan, Fan, Jinshui , Hernandez, Maria O. , Kedei, Noémi , Gorospe, Myriam , Childs, Bennett G. , Martindale, Jennifer L. , Wong, Madeline , Fedorova, Olga V. , Batish, Mona , De, Supriyo , Baker, Darren J. , Herman, Allison B.

Mayo Clinic

No container title available | August 14, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3235572/v1 Get It

Abstract Studying cardiovascular senescence is crucial for understanding disease-related changes in the cardiovascular system and their impact on health and disease. To systematically investigate the heterogeneity of senescent vascular cells in atherosclerosis, we employed the senescence reporter mouse p16tdTomato+/-, overexpressed PCSK9 and fed a high-fat diet (HFD) to induce atherosclerosis, and treated them with the senolytic drug ABT-737. Whole-aorta, single-cell RNA-sequencing (scRNA-seq) and Gene Set Enrichment Analysis (GSEA) using the SenMayo panel uncovered 10 cell clusters displaying senescent features, although not ‘classical’ senescence markers, that were reduced by treatment with ABT-737. Unbiased subclustering revealed subsets of cells increasing by HFD and reduced by ABT-737 treatment that expressed unique transcripts Spp1, Ctsb, and Tnfrsf11b mRNAs. Spatial analysis of these RNAs identified senescent cells in the cap and core of brachiocephalic arteries from atherosclerotic mice. Our results uncover a vascular-specific transcriptomic signature that may be exploited for therapeutic targeting in age-related vascular diseases.
A plain language summary of the long-term relugolix combination therapy study for uterine fibroids
Lukes, Andrea S. , Villarroel, Claudio , McKain, Laura , Li, Yulan , Wagman, Rachel B., Al‐Hendy, Ayman , Venturella, Roberta , Stewart, Elizabeth A.

Mayo Clinic

Journal of Comparative Effectiveness Research | July 21, 2023 | Volume: 12 | Issue: 8 | Pages: No page available

10.57264/cer-2023-0069 | PMID 37477173 Get It

What is this summary about? This is a summary of a research study (known as a clinical trial) called the LIBERTY extension study. The LIBERTY extension study is a long-term study looking at how well a medicine called relugolix combination therapy worked in reducing blood loss during menstrual periods in women with uterine fibroids with heavy menstrual periods. Women were included in the extension study if they finished the 24-week LIBERTY 1 or LIBERTY 2 studies. Heavy menstrual periods were considered to be menstrual blood loss of about one-third of a cup of blood (80 ml) per cycle for two cycles or about two-thirds of a cup of blood (160 ml) during one cycle. The LIBERTY extension study also looked at whether relugolix combination therapy was safe to take for up to 1 year. What were the results? Out of 770 total women with uterine fibroids with heavy menstrual bleeding who took part in the LIBERTY 1 and LIBERTY 2 studies, 476 took part in the LIBERTY extension study. From the start of the LIBERTY 1 and LIBERTY 2 studies through the end of the LIBERTY extension: 163 women took relugolix combination therapy for 52 weeks 149 women took relugolix alone for 12 weeks followed by relugolix combination therapy for 40 weeks 164 women took placebo for 24 weeks followed by relugolix combination therapy for 28 weeks The LIBERTY extension study showed that most women in all three treatment groups responded to relugolix combination therapy by having less bleeding during their menstrual periods, having improved anemia symptoms, and having stable bone mineral loss. Side effects were similar across treatment groups, and the most common side effects were headaches and hot flushes. What do the results mean? Women with uterine fibroids with heavy menstrual bleeding taking relugolix combination therapy may have fewer uterine fibroid bleeding symptoms for up to 1 year of treatment. Clinical Trial Registration: NCT03049735 ( ClinicalTrials.gov ) (LIBERTY 1) Clinical Trial Registration: NCT03103087 ( ClinicalTrials.gov ) (LIBERTY 2) Clinical Trial Registration: NCT03412890 ( ClinicalTrials.gov ) (LIBERTY extension study)
A Plain Language Summary of the Safety of Relugolix Combination Therapy and Improvement in Symptoms in Women with Uterine Fibroids from the LIBERTY 1 and LIBERTY 2 Studies
Lukes, Andrea S. , Poindexter, Alfred N., Villarroel, Claudio , Li, Yulan , McKain, Laura , Ferreira, Juan Camilo Arjona , Langenberg, Andria, Wagman, Rachel B., Al‐Hendy, Ayman , Venturella, Roberta , Critchley, Hilary , Stewart, Elizabeth A.

Mayo Clinic

Pain Management | May 15, 2023 | Volume: 13 | Issue: 4 | Pages: 205-211

10.2217/pmt-2022-0085 | PMID 37183454 Get It

Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in α-Synuclein-Based Mouse Models of Parkinson’s Disease
Ma, Shi-Xun, Seo, Bo Am , Kim, Donghoon , Xiong, Yulan , Kwon, Seung‐Hwan , Brahmachari, Saurav , Kim, Sangjune , Kam, Tae‐In , Kwon, Sang Ho , Dawson, Ted M. , Pandey, Akhilesh , Na, Chan Hyun , Ko, Han Seok , Pandey, Akhilesh , Na, Chan Hyun , Kam, Tae-In , Nirujogi, Raja Sekhar , Dawson, Valina L.

Mayo Clinic

Journal of Proteome Research | June 1, 2021 | Volume: 20 | Issue: 7 | Pages: 3428-3443

10.1021/acs.jproteome.0c01002 | PMID 34061533 Get It